Effect of relative cumulative dose-intensity on survival of patients with urothelial cancer treated with M-VAC.
暂无分享,去创建一个
[1] W. Hryniuk,et al. Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer. , 1987, Seminars in oncology.
[2] S. Piantadosi,et al. The ecological fallacy. , 1988, American journal of epidemiology.
[3] M. Soloway,et al. Cis‐diamminedichloroplatinum (II) in locally advanced and metastatic urothelial cancer , 1981, Cancer.
[4] I. Tannock,et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] W. Whitmore,et al. Adriamycin in advanced urinary tract cancer. Experience in 42 patients and review of the literature , 1977, Cancer.
[6] P. Duffey,et al. The calculation of actual or received dose intensity: a comparison of published methods. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] N. Geller,et al. Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy , 1991, Cancer.
[8] M. Troner,et al. Phase III comparison of cisplatin alone versus cisplatin, doxorubicin and cyclophosphamide in the treatment of bladder (urothelial) cancer: a Southeastern Cancer Study Group trial. , 1987, The Journal of urology.
[9] J. Gabrilove,et al. Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Hryniuk Wm. The importance of dose intensity in the outcome of chemotherapy. , 1988 .
[11] R. Fisher,et al. Phase II evaluation of cis-dichlorodiammineplatinum(II) in advanced malignancies of the genitourinary and gynecologic organs: a Southwest Oncology Group Study. , 1979, Cancer treatment reports.
[12] R. Kefford,et al. A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] L. Einhorn,et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] D. Crowther,et al. Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma. , 1990, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] E. Gehan,et al. Dose‐response and dose‐survival advantage for high versus low‐dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer a southwest oncology group study , 1984, Cancer.
[16] M. Levine,et al. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] S. Fosså,et al. Single‐Drug Chemotherapy with 5‐FU and Adriamycin in Metastatic Bladder Carcinoma , 1981 .
[18] C. Coltman,et al. Adriamycin versus adriamycin plus cis‐diamminedichloroplatinum (DDP) in advanced transitional cell bladder carcinoma: A Southwest Oncology Group study , 1983, American journal of clinical oncology.
[19] S. Fosså,et al. Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder. , 1987, The Journal of urology.
[20] B. Hoogstraten,et al. Dose response evaluation of adriamycin in human neoplasia , 1977, Cancer.
[21] W. H. Kern,et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. , 1991, The Journal of urology.
[22] G. Hortobagyi,et al. Analysis of dose intensity in doxorubicin-containing adjuvant chemotherapy in stage II and III breast carcinoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] H. Herr. Cis-diamminedichloride platinum II in the treatment of advanced bladder cancer. , 1980, The Journal of urology.
[24] S. Hi,et al. Advances in the treatment of urothelial tract tumors. , 1987 .
[25] W. Hryniuk,et al. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] H. Bloom,et al. A Phase 2 Study of Cis‐platinum in Patients with Recurrent Bladder Carcinoma , 1981 .
[27] L. Norton,et al. Chemotherapy for urothelial tract malignancies: breaking the deadlock. , 1992, Seminars in surgical oncology.
[28] M. Soloway,et al. A comparison of cisplatin and the combination of cisplatin and cyclophosphamide in advanced urothelial cancer. A national bladder cancer collaborative group a study , 1983, Cancer.
[29] R. Natale,et al. Phase II trial of vinblastine sulfate for metastatic urothelial tract tumors , 1982, Cancer.
[30] Coppin Cm. The description of chemotherapy delivery: options and pitfalls. , 1987 .
[31] A. Yagoda. Future implications of phase 2 chemotherapy trials in ninety-five patients with measurable advanced bladder cancer. , 1977, Cancer research.
[32] N. Geller,et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. , 1985, The Journal of urology.
[33] S K Carter,et al. Adriamycin. A new anticancer drug with significant clinical activity. , 1974, Annals of internal medicine.
[34] M. Pavone‐Macaluso. Single-drug chemotherapy of bladder cancer with adriamycin, VM-26 or bleomycin. A phase II multicentric, co-operative study. , 1976, European urology.
[35] B. Piura,et al. Experience in the treatment of epithelial ovarian carcinoma with cisplatinum-containing combination chemotherapy and dose intensity calculation. , 1990, European journal of gynaecological oncology.
[36] P. Drings. European experience with ifosfamide in non-small cell lung cancer. , 1989, Seminars in oncology.
[37] P. Elson,et al. Comparative activity and toxicity of cis-diamminedichloroplatinum (DDP) and a combination of doxorubicin, cyclophosphamide, and DDP in disseminated transitional cell carcinomas of the urinary tract. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] H. Lazarus,et al. High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: an update. , 1987, Seminars in oncology.
[39] N. Geller,et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse , 1989, Cancer.